BioNTech, Q3 2024

BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, investor relations. Please go ahead. Michael Horowicz-- Vice President,
BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.
BioNTech SE (NASDAQ:BNTX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
Marqeta (MQ) Q3 2024 Earnings Call Transcript
At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator instructions] As a reminder, this conference is being recorded.
Brightcove Inc. (BCOV) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ETCompany ParticipantsMarc DeBevoise - Chief Executive
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Nov 04, 2024, 5:00 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Partici
BioNTech price target lowered to $122 from $132 at TD Cowen
TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $122 from $132 and keeps a Hold rating on the shares. The firm noted ...
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...
FiercePharma1d
BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
BioNTech’s Strong Oncology Pipeline and COVID-19 Vaccine Performance Earns Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
BioSpace1d
BioNTech Handily Beats Q3 Expectations, Trims Full-Year Revenue Guidance
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
ETF Daily News3d
BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat ...
MarketWatch3d
BioNTech SE ADR falls Friday, underperforms market
The BioNTech SE ADR BNTX shed 1.43% to $111.48 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.41% to 5,728.80 and ...
Seeking Alpha17d
BioNTech and Moderna: A tale of two mRNA developers
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...